We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Risk of Colorectal Cancer Linked to Composition of the Gut Microbiome

By LabMedica International staff writers
Posted on 17 Dec 2013
The composition of the community of bacteria living in the digestive tract has been linked to the risk of developing colorectal cancer (CRC).

Colorectal cancer is diagnosed in about 143,000 Americans annually with nearly 51,000 fatalities, making it second only to lung cancer in the number of deaths caused each year. However, it is not well understood why colorectal cancer develops.

Investigators at the New York University School of Medicine (NY, USA) tested the hypothesis that an altered community of gut microbes was associated with risk of developing CRC. To this end, they compared the DNA composition of intestinal microbes in the stool samples of 47 CRC patients and 94 healthy volunteers.

16S rRNA genes in fecal bacterial DNA were amplified by universal primers, sequenced by Roche (Basel, Switzerland) 454 FLX technology, and aligned for taxonomic classification to microbial genomes using the QIIME protocol.

QIIME, which stands for Quantitative Insights into Microbial Ecology, is an open source software package for comparison and analysis of microbial communities, primarily based on high-throughput amplicon sequencing data generated on a variety of platforms, but also supporting analysis of other types of data. QIIME chaperones users from their raw sequencing output through initial analyses such as OTU (operational taxonomic unit) picking, taxonomic assignment, and construction of phylogenetic trees from representative sequences of OTUs, and through downstream statistical analysis, visualization, and production of publication-quality graphics. QIIME has been applied to studies based on billions of sequences from thousands of samples.

Taxonomic differences identified in this study were confirmed by quantitative polymerase chain reaction (qPCR) and adjusted for false discovery rate. Data from 794,217 16S rRNA gene sequences revealed that CRC case subjects had decreased overall microbial community diversity. In taxonomy-based analyses, lower relative abundance of Clostridia and increased carriage of Fusobacterium and Porphyromonas were found in case subjects compared with control subjects. Clostridia include some bacterial family members that ferment dietary fiber to butyrate, which is a major colonic metabolite that may inhibit inflammation and carcinogenesis in the colon, while Fusobacterium and Porphyromonas are related to inflammation in the mouth and gastrointestinal track.

"Our findings are important because identification of these microbes may open the door for colorectal cancer prevention and treatment," said first author Dr. Jiyoung Ahn, assistant professor of population health at the New York University School of Medicine. "Our next step is to study how diet and lifestyle factors modulate these gut bacteria associated with colorectal cancer. This may lead to ways to prevent this disease."

The paper was published in the December 6, 2013, online edition of the Journal of the [US] National Cancer Institute.

Related Links:
New York University School of Medicine
Roche
QIIME


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more